COST-EFFECTIVENESS ANALYSIS OF EXENATIDE ONCE-WEEKLY VERSUS DULAGLUTIDE, LIRAGLUTIDE AND LIXISENATIDE FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM THE UK NHS PERSPECTIVE

被引：1
|
作者：
Charokopou, M. [1 ]
Chuang, L. [1 ]
Verheggen, B. [1 ]
Gibson, D. [2 ]
Grandy, S. [3 ]
Kartman, B. [4 ]
机构：
[1] Pharmerit Int, Rotterdam, Netherlands
[2] AstraZeneca, Luton, Beds, England
[3] Astrazeneca Pharmaceut LP, Gaithersburg, MD USA
[4] AstraZeneca, Molndal, Sweden
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2090
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB50
引用
收藏
页码：A606 / A606
页数：1
相关论文
共 50 条
  • [41] Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
    Arslanian, Silva A.
    Hannon, Tamara
    Zeitler, Philip
    Chao, Lily C.
    Boucher-Berry, Claudia
    Barrientos-Perez, Margarita
    Bismuth, Elise
    Dib, Sergio
    Cho, Jang Ik
    Cox, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (05): : 433 - 443
  • [42] Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes
    Senoo, Yuki
    Kami, Masahiro
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (16): : 1529 - 1530
  • [43] Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11
    Evans, Marc
    Chubb, Barrie
    Malkin, Samuel J. P.
    Berry, Sasha
    Lawson, Jack
    Hunt, Barnaby
    DIABETES OBESITY & METABOLISM, 2023, 25 (02): : 491 - 500
  • [44] COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN THE UK
    Schlueter, M.
    Vega-Hernandez, G.
    Wojcik, R.
    VALUE IN HEALTH, 2016, 19 (07) : A675 - A675
  • [45] Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting
    Hunt, Barnaby
    Vega-Hernandez, Gabriela
    Valentine, William J.
    Kragh, Nana
    DIABETES OBESITY & METABOLISM, 2017, 19 (06): : 842 - 849
  • [46] THE IMPACT OF LONG-TERM CLINICAL EVIDENCE ON COST-EFFECTIVENESS OF EXENATIDE ONCE WEEKLY (BYDUREON®) VERSUS INSULIN GLARGINE FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) FROM A UK NHS PERSPECTIVE
    Charokopou, M.
    Vioix, H.
    Verheggen, B. G.
    Bratt, T.
    Franks, D.
    VALUE IN HEALTH, 2014, 17 (07) : A343 - A343
  • [47] COST UTILITY ANALYSIS OF ONCE-WEEKLY SEMAGLUTIDE AND DULAGLUTIDE FOR PATIENTS WITH TYPE 2 DIABETES IN SAUDI ARABIA
    Hassan, M.
    Barham, L.
    VALUE IN HEALTH, 2023, 26 (12) : S54 - S54
  • [48] Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes Response
    Arslanian, Silva A.
    Cox, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (16): : 1530 - 1531
  • [49] The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France
    Mickael Basson
    Dionysios Ntais
    Ruba Ayyub
    Donna Wright
    Julia Lowin
    Florence Chartier
    Stéphane Roze
    Kirsi Norrbacka
    Diabetes Therapy, 2018, 9 : 13 - 25
  • [50] The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France
    Basson, Mickael
    Ntais, Dionysios
    Ayyub, Ruba
    Wright, Donna
    Lowin, Julia
    Chartier, Florence
    Roze, Stephane
    Norrbacka, Kirsi
    DIABETES THERAPY, 2018, 9 (01) : 13 - 25
12345